



ICIEM  2025 KYOTO

September
2(Tue) - 6(Sat) 2025

Long-term clinical outcomes of patients with acute hepatic porphyria who were not attack-free after 6-months of givosiran treatment: a subgroup analysis of the phase 3 ENVISION study

Eliane Sardh,* Paolo Ventura,¹ Encarna Guillen-Navarro,^{2,3} Bruce Wang,⁴ Weiming Du,⁵ Ana Camejo,⁵ Manish Thapar⁶

*Presenting on behalf of the authors, Department of Molecular Medicine and Surgery, Centre for Inherited Metabolic Diseases, Porphyria Centre Sweden, and Department of Endocrinology, Karolinska Institutet, Karolinska University, ¹Internal Medicine Unit, University of Modena and Reggio Emilia, Modena, Italy; ²Medical Genetics Section, Virgen de la Arrixaca University Hospital, IMIB Pascual Parrilla, University of Murcia (UMU), Murcia, Spain; ³CIBERER-ISCIII, Madrid, Spain; ⁴UCSF Health, San Francisco, United States; ⁵Alnylam Pharmaceuticals, Cambridge, United States; ⁶Thomas Jefferson University, Philadelphia, United States



ICIEM 2025 KYOTO

September
2(Tue) - 6(Sat) 2025

ICIEM 2025 COI Disclosure

Eliane Sardh received grant support and personal fees, paid to Karolinska Institutet, from Alnylam Pharmaceuticals.

Paolo Ventura received consultancy fees and honoraria from Alnylam Pharmaceuticals and Recordati Rare Disease

Encarna Guillen-Navarro received grants/research support, paid to the Fundación para la Formación e Investigación Biosanitaria-FFIS, from Alnylam Pharmaceuticals and consulting fees from Alnylam Pharmaceuticals, BioMarin, and UCB

Bruce Wang is a scientific advisor to Alnylam Pharmaceuticals and Recordati Rare Diseases.

Weiming Du is an employee of and owns stock and stock options in Alnylam Pharmaceuticals

Ana Camejo was an employee of and shareholder in Alnylam Pharmaceuticals at the time of the study

Manish Thapar is a consultant and speaker for Alnylam Pharmaceuticals and has served as a consultant for Disc Medicine, Mitsubishi Tanabe, and Recordati Rare Diseases

Funding: This study is funded by Alnylam Pharmaceuticals

Acknowledgements: Under the direction of the authors, medical writing support was provided by Ester Baixauli PhD of Oxford PharmaGenesis, Oxford, UK, and was funded by Alnylam Pharmaceuticals



ICIEM  **2025** KYOTO

September
2(Tue) - **6**(Sat) **2025**

**Scan this QR code to access a copy of the ENVISION presentation
on the AInylam ICIEM 2025 microsite**


**For US HCPs Only
Scan to view congress
materials**





Background

- Acute hepatic porphyria (AHP) is a group of four rare, genetic, multisystemic disorders caused by defects in the heme biosynthesis pathway¹
- Defects cause the accumulation of δ -aminolevulinic acid (ALA) and porphobilinogen (PBG)²
- Patients with AHP can experience:¹
 - acute attacks
 - chronic symptoms
 - progressive elements
 - long-term complications
- Givosiran is an RNAi therapy that reduces accumulation of ALA and PBG²
 - Approved in the USA, Brazil, Taiwan, and Canada for the treatment of adults with AHP
 - Approved in the EU, Switzerland, and Japan for the treatment of adults and adolescents (≥ 12 years of age) with AHP



Symptoms **in bold** are those most commonly experienced by patients with AHP



ENVISION: overview

A multicentre, randomized, double-blind, placebo-controlled, phase 3 study (NCT03338816)

- In the ENVISION study, sustained reductions in annualized attack rate with givosiran were observed^{1,2}
 - 58% of patients who completed the study through month 36 were attack-free after the first 6-months of givosiran treatment and for the study duration²
- We examined long-term outcomes in patients who were, and were not attack-free after the first 6-months of givosiran treatment



ENVISION: study design

Eligibility criteria

- AHP diagnosis
- ≥ 12 years of age
- ≥ 2 attacks requiring hospitalization, urgent care, or intravenous hemin at home during the 6-months before study enrolment

1:1 randomization

6-month
DB period

Givosiran
2.5 mg/kg
monthly

Placebo

30-month
OLE period

Givosiran
1.25 mg/kg
monthly, or
2.5 mg/kg
monthly^a

Post hoc descriptive analysis

- Comprised patients who had completed the DB and OLE periods
- Subgroups were defined based on attack frequency after the first 6-months of givosiran treatment
 - Attack-free: patients with 0 attacks
 - Not attack-free: patients with ≥ 1 attack

^aThe dose could be increased from 1.25 mg/kg to 2.5 mg/kg monthly or after month 13 in those who experienced inadequate control on the 1.25 mg/kg dose. Per a subsequent protocol amendment, the 1.25 mg/kg dose was increased to 2.5 mg/kg monthly in the remaining patients. AHP, acute hepatic porphyria; DB, double-blind; OLE, open-label extension



Baseline demographics and disease characteristics

- In total, 94 patients were randomized; 79 completed the study
 - 46 (58%) patients were attack-free
 - 33 (42%) patients were not attack free
- For patients who were not attack-free, mean composite AAR (attacks requiring hospitalization, urgent care, or intravenous hemin at home) after >0–6-months of givosiran treatment was 7.0 (range, 0.0-23.9)



Baseline demographics and disease characteristics


Demographic/characteristic ^a	Attack-free ^b (n=46)	Not attack-free ^c (n=33)	All patients treated with givosiran (N=79)
Age at screening, years, median (min, max)	41.5 (19.0, 61.0)	36.0 (20.0, 57.0)	38.0 (19.0, 61.0)
Time since diagnosis, years, mean (SD)	9.43 (10.00)	10.32 (9.92)	9.80 (9.91)
Age at diagnosis, years, mean (SD)	32.44 (11.39)	26.70 (9.03)	30.04 (10.79)
Female, n (%)	39 (84.8)	31 (93.9)	70 (88.6)
Prior hemin prophylaxis regimen, n (%)	18 (39.1)	13 (39.4)	31 (39.2)
Prior chronic symptoms when not having attacks, n (%)	23 (50.0)	20 (60.6)	43 (54.4)
Prior chronic opioid use when not having attacks, n (%)	13 (28.3)	10 (30.3)	23 (29.1)
History of depression, n (%)	11 (23.9)	13 (39.4)	24 (30.4)
History of hypertension, n (%)	11 (23.9)	10 (30.3)	21 (26.6)
History of neuropathy, n (%)	18 (39.1)	13 (39.4)	31 (39.2)

^aThe demographics and disease characteristics at the double-blind period baseline were summarized; ^bPatients with 0 attacks; ^cPatients with ≥ 1 attack after the first 6-months of givosiran treatment and for the study duration. Max, maximum; min, minimum; N, total number of patients included; n, patients included per subgroup; SD, standard deviation



Mean composite AAR per 6-month interval decreased over time for patients who were in the 'Not attack-free' group

- Mean % reductions relative to historical composite AAR (mean [SD], 12.8 [9.6]):
 - -39.7% after >0-6-months of givosiran treatment
 - -85.4% after >30-36-months of givosiran treatment
- Patients who were attack-free remained attack-free throughout the 36-months of the study




AAR were attacks requiring hospitalization, urgent care, or intravenous hemin at home. Baseline represents 6-months before randomization. Error bars show SDs. Data on arrows show mean % change from baseline in mean composite AAR. ^aComposite attacks were attacks requiring hospitalization, urgent care, or intravenous hemin at home; ^bPatients with 0 attacks; ^cPatients with ≥ 1 attack after the first 6-months of givosiran treatment and for the study duration. AAR, annualized attack rate; SD, standard deviation




Number of patients in the 'not attack-free' group who became attack-free with continued treatment increased with each additional 6-month interval

- Not attack-free group:
 - 9% attack-free after >6-12-months of treatment
 - 79% after >30-36-months of treatment





Median urinary PBG levels decreased over time




No. of patients:

Attack free ^a	46	46	46	46	45	45	45	43	43	45	45	22	24
% change ^c			-88.5								-94.7		-97.2
Not attack free ^b	33	32	31	33	31	32	33	32	31	32	31	16	16
% change ^c			-86.3								-93.8		-93.4
Total	79	78	77	79	76	77	78	75	74	77	76	38	40
% change ^c			-88.1								-94.6		-95.9

For patients who received placebo in the DB period and givosiran in OLE period, the data only included post givosiran treatment with baseline redefined relative to the first dose of givosiran and analysis visits mapped based on redefined baseline. Data on arrows show median % change from baseline in PBG levels. ^aPatients with 0 attacks; ^bPatients with ≥ 1 attack after the first 6-months of givosiran treatment and for the study duration; ^cPercentage change from baseline. DB, double blind, N, total number of patients included; n, patients included per subgroup; OLE, open-label extension; PBG, porphobilinogen



Median urinary ALA levels decreased over time




No. of patients:

Attack free ^a	46	46	46	46	45	45	45	43	43	45	45	22	24
% change ^c			-87.5									-92.6	-92.7
Not attack free ^b	33	32	31	33	31	32	33	32	31	33	31	16	16
% change ^c			-84.8								-90.0	-91.6	
Total	79	78	77	79	76	77	78	75	74	78	76	38	40
% change ^c			-86.0								-92.3	-92.7	

For patients who received placebo in the DB period and givosiran in OLE period, the data only included post givosiran treatment with baseline redefined relative to the first dose of givosiran and analysis visits mapped based on redefined baseline. Data on arrows show median % change from baseline in median ALA levels. ^aPatients with 0 attacks; ^bPatients with ≥ 1 attack after the first 6-months of givosiran treatment and for the study duration. ^cPercentage median change from baseline. ALA, δ -aminolevulinic acid; DB, double blind; N, total number of patients included; n, patients included per subgroup; OLE, open-label extension



EQ-VAS scores improved in both groups




Change from baseline, mean±SEM (n)	Attack-free ^a (n=46)	Not attack-free ^b (n=33)	All patients treated with givosiran (N=79)
Baseline	68.1±3.2 (46)	62.0±3.9 (33)	65.6±2.5 (79)
After 6-months of treatment	6.9±3.0 (46)	2.2±3.5 (33)	4.9±2.3 (79)
After 30-months of treatment	10.9±3.3 (44)	10.9±4.4 (29)	10.9±2.6 (73)
After 36-months of treatment	19.9±4.6 (23)	17.5±6.4 (17)	18.9±3.7 (40)

For patients who received placebo in the DB period and givosiran in OLE period, the data only included post givosiran treatment with baseline redefined relative to the first dose of givosiran and analysis visits mapped based on redefined baseline. Error bars show SEM. Baseline is shown at 0 months and it represents 6-months before randomization. Data on arrows show absolute mean change from baseline in EQ-VAS.

Estimates for the clinically meaningful difference are ≥7 to 8 points for EQ-VAS. ^aPatients with 0 attacks; ^bPatients with ≥1 attack after the first 6-months of givosiran treatment and for the study duration EQ-VAS, EuroQol visual analogue scale; DB, double blind; N, total number of patients included; n, patients included in each subgroup; OLE, open-label extension; SEM, standard error of the mean



SF-12 version 2 PCS scores improved in both groups



Change from baseline, mean±SEM (n)	Attack-free ^a (n=46)	Not attack-free ^b (n=33)	All patients treated with givosiran (N=79)
Baseline	40.5±1.3 (46)	38.1±1.8 (33)	39.5±1.1 (79)
After 6-months of treatment	7.3±1.3 (45)	4.1±1.4 (33)	6.0±1.0 (78)
After 30-months of treatment	8.5±1.2 (44)	8.0±2.0 (29)	8.3±1.1 (73)
After 36-months of treatment	8.3±1.7 (23)	9.1±3.2 (17)	8.6±1.6 (40)

For patients who received placebo in the DB period and givosiran in OLE period, the data only included post givosiran treatment with baseline redefined relative to the first dose of givosiran and analysis visits mapped based on redefined baseline. Error bars show SEM. Baseline is shown at 0 months and it represents 6-months before randomization. Data on arrows show absolute mean change from baseline in SF-12 score points. **Estimates for the clinically meaningful difference are 2 to 5 points for SF-12.** ^aPatients with 0 attacks; ^bPatients with ≥1 attack after the first 6-months of givosiran treatment and for the study duration. DB, Double blind, N, total number of patients included; n, patients included in each subgroup; OLE, open-label extension; PCS, Physical Component Summary; SEM, standard error of the mean; SF-12, 12-item Short Form Health Survey.



ENVISION: summary of *post hoc* analyses

- Both patient groups had reduced attacks and other treatment-related improvements within the first 6-months of givosiran treatment
- Patients who were not attack-free after the first 6-months of treatment experienced further attack reductions and HRQoL life improvements with long-term givosiran treatment
- Patients who were attack-free remained attack-free and report HRQoL improvements through month 36

Results of this analysis indicate that long-term givosiran treatment provides sustained improvements in health outcomes for patients, regardless of attack status



ICIEM  **2025** KYOTO

September
2(Tue) - **6**(Sat) **2025**

**Thank you to the patients, their families, investigators, study staff,
and collaborators for their participation in the ENVISION study**

**For US HCPs only;
scan to view interactive
Infographic of ENVISION
post hoc study data**

